These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 22812559)

  • 21. Cost-effectiveness of a pentavalent human-bovine reassortant rotavirus vaccine for children ≤5 years of age in Taiwan.
    Itzler RF; Chen PY; Lac C; El Khoury AC; Cook JR
    J Med Econ; 2011; 14(6):748-58. PubMed ID: 21919673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of varicella serotesting versus presumptive vaccination of school-age children and adolescents.
    Lieu TA; Finkler LJ; Sorel ME; Black SB; Shinefield HR
    Pediatrics; 1995 May; 95(5):632-8. PubMed ID: 7724297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Regional variation in the cost effectiveness of childhood hepatitis A immunization.
    Jacobs RJ; Greenberg DP; Koff RS; Saab S; Meyerhoff AS
    Pediatr Infect Dis J; 2003 Oct; 22(10):904-14. PubMed ID: 14551492
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness of rotavirus vaccination as part of the national immunization program for Thai children.
    Chotivitayatarakorn P; Chotivitayatarakorn P; Poovorawan Y
    Southeast Asian J Trop Med Public Health; 2010 Jan; 41(1):114-25. PubMed ID: 20578490
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of male HPV vaccination in the United States.
    Chesson HW; Ekwueme DU; Saraiya M; Dunne EF; Markowitz LE
    Vaccine; 2011 Oct; 29(46):8443-50. PubMed ID: 21816193
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The cost-effectiveness of introducing hepatitis B vaccine into infant immunization services in Mozambique.
    Griffiths UK; Hutton G; Das Dores Pascoal E
    Health Policy Plan; 2005 Jan; 20(1):50-9. PubMed ID: 15689430
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-effectiveness of influenza vaccination of healthy children.
    Salo H; Kilpi T; Sintonen H; Linna M; Peltola V; Heikkinen T
    Vaccine; 2006 Jun; 24(23):4934-41. PubMed ID: 16678945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Reassessing the cost-effectiveness of meningococcal serogroup C conjugate (MCC) vaccines using a transmission dynamic model.
    Trotter CL; Edmunds WJ
    Med Decis Making; 2006; 26(1):38-47. PubMed ID: 16495199
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Valuing vaccines: deficiencies and remedies.
    Bloom DE
    Vaccine; 2015 Jun; 33 Suppl 2():B29-33. PubMed ID: 26022563
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy.
    Giorgi-Rossi P; Merito M; Borgia P
    Health Policy; 2009 Feb; 89(2):225-38. PubMed ID: 18639952
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness of influenza vaccination of people aged 50-64 years in Australia: results are inconclusive.
    Mogasale V; Barendregt J
    Aust N Z J Public Health; 2011 Apr; 35(2):180-6. PubMed ID: 21463417
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Influence of clinical case definitions with differing levels of sensitivity and specificity on estimates of the relative and absolute health benefits of influenza vaccination among healthy working adults and implications for economic analyses.
    Nichol KL; Mendelman P
    Virus Res; 2004 Jul; 103(1-2):3-8. PubMed ID: 15163481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potential impact and cost-effectiveness analysis of rotavirus vaccination of children in Israel.
    Chodick G; Waisbourd-Zinman O; Shalev V; Kokia E; Rabinovich M; Ashkenazi S
    Eur J Public Health; 2009 Jun; 19(3):254-9. PubMed ID: 19221026
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Could a federal program to promote influenza vaccination among elders be cost-effective?
    Patel MS; Davis MM
    Prev Med; 2006 Mar; 42(3):240-6. PubMed ID: 16480761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The cost-effectiveness of alternative polio immunization policies in South Africa.
    Griffiths UK; Botham L; Schoub BD
    Vaccine; 2006 Jul; 24(29-30):5670-8. PubMed ID: 16766096
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Economic Analysis of Vaccination Programs: An ISPOR Good Practices for Outcomes Research Task Force Report.
    Mauskopf J; Standaert B; Connolly MP; Culyer AJ; Garrison LP; Hutubessy R; Jit M; Pitman R; Revill P; Severens JL
    Value Health; 2018 Oct; 21(10):1133-1149. PubMed ID: 30314613
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Social Value Of Vaccination Programs: Beyond Cost-Effectiveness.
    Luyten J; Beutels P
    Health Aff (Millwood); 2016 Feb; 35(2):212-8. PubMed ID: 26858372
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Markov models in dentistry: application to resin-bonded bridges and review of the literature.
    Mahl D; Marinello CP; Sendi P
    Expert Rev Pharmacoecon Outcomes Res; 2012 Oct; 12(5):623-9. PubMed ID: 23186403
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analyses of vaccination programmes : a focused review of modelling approaches.
    Kim SY; Goldie SJ
    Pharmacoeconomics; 2008; 26(3):191-215. PubMed ID: 18282015
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.